{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:23:04Z","timestamp":1786990984019,"version":"build-2736575974"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.intimp.2022.108595","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T15:54:47Z","timestamp":1643903687000},"page":"108595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes"],"prefix":"10.1016","volume":"106","author":[{"given":"Saba","family":"Bakhshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeedeh","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108595_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105710","article-title":"Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"170","author":"\u00d6zenver","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12296","article-title":"Regulation of inflammasome activation","volume":"265","author":"Man","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2022.108595_b0015","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3389\/fimmu.2020.01840","article-title":"Human autoinflammatory diseases mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-inflammasome dysregulation updates on diagnosis, treatment, and the respective roles of IL-1 and IL-18","volume":"11","author":"Alehashemi","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0020","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12026-015-8751-0","article-title":"Atrial natriuretic peptide down-regulates LPS\/ATP-mediated IL-1\u03b2 release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1 activation in THP-1 cells","volume":"64","author":"Mezzasoma","year":"2016","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0035","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.intimp.2022.108595_b0040","doi-asserted-by":"crossref","DOI":"10.5551\/jat.RV17001","article-title":"Role of NLRP3 inflammasomes in atherosclerosis","author":"Karasawa","year":"2017","journal-title":"J. Atherosclerosis Thrombosis"},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0045","article-title":"Targeting the NLRP3 inflammasome in neuroinflammation: health promoting effects of dietary phytochemicals in neurological disorders","volume":"64","author":"Hung","year":"2020","journal-title":"Mol. Nutr. Food Res."},{"issue":"7","key":"10.1016\/j.intimp.2022.108595_b0050","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.4049\/jimmunol.0900576","article-title":"Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells","volume":"183","author":"Bradshaw","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108595_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fcell.2020.00106","article-title":"Role of inflammasomes in kidney diseases via both canonical and non-canonical pathways","volume":"8","author":"Xiang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0060","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/ijms20122876","article-title":"Phytochemicals as novel therapeutic strategies for NLRP3 inflammasome-related neurological, metabolic, and inflammatory diseases","volume":"20","author":"Pellegrini","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.gastro.2019.09.040","article-title":"NLRP3 inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis","volume":"158","author":"Sendler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.108595_b0070","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0075","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"465","key":"10.1016\/j.intimp.2022.108595_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2022.108595_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2019.04.004","article-title":"MCC950 blocks enhanced interleukin-1\u03b2 production in patients with NLRP3 low penetrance variants","volume":"203","author":"Schuh","year":"2019","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10067-018-4331-8","article-title":"Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene","volume":"38","author":"Iida","year":"2019","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11076-1","article-title":"Alternative splicing regulates stochastic NLRP3 activity","volume":"10","author":"Hoss","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0110","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202006194","article-title":"The NLRP3\u2013inflammasome as a sensor of organelle dysfunction","volume":"219","author":"Seoane","year":"2020","journal-title":"J. Cell Biol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108595_b0115","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"10.1016\/j.intimp.2022.108595_b0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0968-0004(00)01577-2","article-title":"The NACHT family\u2013a new group of predicted NTPases implicated in apoptosis and MHC transcription activation","volume":"25","author":"Koonin","year":"2000","journal-title":"Trends Biochem. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nri.2016.151","article-title":"Homeostasis-altering molecular processes as mechanisms of inflammasome activation","volume":"17","author":"Liston","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"issue":"43","key":"10.1016\/j.intimp.2022.108595_b0135","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","article-title":"Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation","volume":"287","author":"Juliana","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2022.108595_b0145","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.cub.2004.10.027","article-title":"Identification of bacterial muramyl dipeptide as activator of the NALP3\/cryopyrin inflammasome","volume":"14","author":"Martinon","year":"2004","journal-title":"Curr. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3906\/biy-1909-31","article-title":"The NLRP3 inflammasome: a new player in neurological diseases","volume":"43","author":"Eren","year":"2019","journal-title":"Turkish J. Biol."},{"issue":"7081","key":"10.1016\/j.intimp.2022.108595_b0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature04517","article-title":"Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin\/Nalp3","volume":"440","author":"Kanneganti","year":"2006","journal-title":"Nature"},{"issue":"7329","key":"10.1016\/j.intimp.2022.108595_b0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41580-018-0052-8","article-title":"The machineries, regulation and cellular functions of mitochondrial calcium","volume":"19","author":"Giorgi","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108595_b0170","doi-asserted-by":"crossref","first-page":"10835","DOI":"10.1096\/fj.202000734R","article-title":"Endoplasmic reticulum stress-dependent activation of iNOS\/NO-NF-\u03baB signaling and NLRP3 inflammasome contributes to endothelial inflammation and apoptosis associated with microgravity","volume":"34","author":"Jiang","year":"2020","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.intimp.2022.108595_b0175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.immuni.2015.10.009","article-title":"Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock","volume":"43","author":"Yang","year":"2015","journal-title":"Immunity"},{"issue":"7371","key":"10.1016\/j.intimp.2022.108595_b0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"issue":"7521","key":"10.1016\/j.intimp.2022.108595_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2022.108595_b0190","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/eji.201545772","article-title":"Caspase-11 activates a canonical NLRP3 inflammasome by promoting K+ efflux","volume":"45","author":"R\u00fchl","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9761","article-title":"Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes","volume":"6","author":"Vigan\u00f2","year":"2015","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2022.108595_b0200","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/molecules25102427","article-title":"Does NLRP3 inflammasome and aryl hydrocarbon receptor play an interlinked role in bowel inflammation and colitis-associated colorectal cancer?","volume":"25","author":"Ngui","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0205","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0210","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","article-title":"De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases","volume":"46","author":"Aksentijevich","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/db12-1115","article-title":"Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant?","volume":"62","author":"Dixit","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2022.108595_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2017.06.002","article-title":"Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review","volume":"74","author":"Rheinheimer","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2022.108595_b0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2017.10.027","article-title":"NLRP3 inflammasome pathways in atherosclerosis","volume":"267","author":"Baldrighi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.intimp.2022.108595_b0235","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.abb.2019.01.031","article-title":"The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout","volume":"670","author":"Szekanecz","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0240","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.hlc.2013.01.012","article-title":"NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis","volume":"22","author":"Zheng","year":"2013","journal-title":"Heart, Lung and Circulation"},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0245","article-title":"The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans","volume":"11","author":"Liu","year":"2017","journal-title":"J. Crohn\u2019s and Colitis"},{"issue":"5","key":"10.1016\/j.intimp.2022.108595_b0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/BOR.0000000000000088","article-title":"The Inflammasome and lupus-another innate immune mechanism contributing to disease pathogenesis?","volume":"26","author":"Kahlenberg","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0255","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/keu318","article-title":"Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages","volume":"54","author":"Yang","year":"2015","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0260","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/acs.jafc.7b05113","article-title":"Beneficial properties of phytochemicals on NLRP3 inflammasome-mediated gout and complication","volume":"66","author":"Jhang","year":"2018","journal-title":"J. Agric. Food. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0265","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/med.21781","article-title":"NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications","volume":"41","author":"Pellegrini","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.intimp.2022.108595_b0270","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biopha.2017.01.060","article-title":"The cardioprotective effect of total flavonoids on myocardial ischemia\/reperfusion in rats","volume":"88","author":"Lv","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0275","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/ATVBAHA.114.303763","article-title":"Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II\u2013induced aortic aneurysm","volume":"35","author":"Usui","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.intimp.2022.108595_b0280","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fimmu.2016.00313","article-title":"A deeper look into type 1 diabetes\u2013imaging immune responses during onset of disease","volume":"7","author":"Christoffersson","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0285","first-page":"187","article-title":"Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections","volume":"18","author":"Moutschen","year":"1992","journal-title":"Diab. Metabolisme"},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0290","doi-asserted-by":"crossref","first-page":"e1000661","DOI":"10.1371\/journal.ppat.1000661","article-title":"IL-1\u03b2 processing in host defense: beyond the inflammasomes","volume":"6","author":"Netea","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2022.108595_b0295","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fimmu.2017.00164","article-title":"Mitochondrial DNA activates the NLRP3 inflammasome and predisposes to type 1 diabetes in murine model","volume":"8","author":"Carlos","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"issue":"37","key":"10.1016\/j.intimp.2022.108595_b0305","doi-asserted-by":"crossref","first-page":"15324","DOI":"10.1073\/pnas.1100255108","article-title":"Inflammasome is a central player in the induction of obesity and insulin resistance","volume":"108","author":"Stienstra","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0310","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ni.3659","article-title":"Postprandial macrophage-derived IL-1\u03b2 stimulates insulin, and both synergistically promote glucose disposal and inflammation","volume":"18","author":"Dror","year":"2017","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0315","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0320","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","article-title":"Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases","volume":"51","author":"Sanna","year":"2019","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0325","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/antiox9090848","article-title":"Microbiota-mitochondria inter-talk: a potential therapeutic strategy in obesity and type 2 diabetes","volume":"9","author":"Vezza","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.intimp.2022.108595_b0330","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biocel.2018.02.015","article-title":"mROS-TXNIP axis activates NLRP3 inflammasome to mediate renal injury during ischemic AKI","volume":"98","author":"Wen","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0335","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","article-title":"The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1\u2013mediated tissue injury","volume":"93","author":"Anders","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2022.108595_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies","author":"Zhao","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2022.108595_b0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fmolb.2020.00037","article-title":"MCC950, a selective inhibitor of NLRP3 inflammasome, reduces the inflammatory response and improves neurological outcomes in mice model of spinal cord injury","volume":"7","author":"Jiao","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"23","key":"10.1016\/j.intimp.2022.108595_b0350","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.3390\/molecules25235533","article-title":"Inhibiting the NLRP3 inflammasome","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0355","doi-asserted-by":"crossref","first-page":"e3000354","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0360","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2022.108595_b0365","doi-asserted-by":"crossref","first-page":"247","DOI":"10.12688\/wellcomeopenres.16107.1","article-title":"The NLRP3 inhibitor MCC950 inhibits IL-1\u03b2 production in PBMC from 19 patients with Cryopyrin-Associated Periodic Syndrome and in 2 patients with Schnitzler\u2019s Syndrome","volume":"5","author":"Corcoran","year":"2020","journal-title":"Wellcome Open Research"},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0370","first-page":"828","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"Van Hout","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.intimp.2022.108595_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.04.022","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction","volume":"74","author":"Gao","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108595_b0380","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E\u2013deficient mice\u2014brief report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108595_b0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1166\/jbn.2020.2885","article-title":"Precisely and Efficiently Enzyme Response Microspheres with Immune Removal Escape Loaded with MCC950 Ameliorate Cardiac Dysfunction in Acute Myocardial Infarction","volume":"16","author":"Cheng","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108595_b0390","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014044","article-title":"Targeting the NLRP 3 Inflammasome With Inhibitor MCC 950 Prevents Aortic Aneurysms and Dissections in Mice","volume":"9","author":"Ren","year":"2020","journal-title":"J. Am. Heart Association"},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0395","article-title":"Protective effects of NLRP3 inhibitor MCC950 on sepsis-induced myocardial dysfunction","volume":"35","author":"Li","year":"2021","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.intimp.2022.108595_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112133","article-title":"MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis","volume":"143","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2022.108595_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108305","article-title":"NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia","volume":"180","author":"Hull","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0410","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/molecules23030522","article-title":"Inhibiting the NLRP3 inflammasome activation with MCC950 ameliorates diabetic encephalopathy in db\/db mice","volume":"23","author":"Zhai","year":"2018","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.intimp.2022.108595_b0415","doi-asserted-by":"crossref","first-page":"e2941","DOI":"10.1038\/cddis.2017.308","article-title":"Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2022.108595_b0420","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/DMSO.S199802","article-title":"A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation","volume":"12","author":"Zhang","year":"2019","journal-title":"Diabetes, metabolic syndrome and obesity: targets and therapy"},{"issue":"8","key":"10.1016\/j.intimp.2022.108595_b0425","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/gerona\/glz239","article-title":"NLRP3 inflammasome inhibition by MCC950 in aged mice improves health via enhanced autophagy and PPAR\u03b1 activity","volume":"75","author":"Mar\u00edn-Aguilar","year":"2020","journal-title":"J. Gerontol.: Series A"},{"key":"10.1016\/j.intimp.2022.108595_b0430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnint.2020.00037","article-title":"Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases","volume":"14","author":"Guan","year":"2020","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.intimp.2022.108595_b0435","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0440","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00221-020-05916-6","article-title":"Protection of MCC950 against Alzheimer\u2019s disease via inhibiting neuronal pyroptosis in SAMP8 mice","volume":"238","author":"Li","year":"2020","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.intimp.2022.108595_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0450","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1002\/jcb.27792","article-title":"Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis","volume":"120","author":"Xu","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.intimp.2022.108595_b0455","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143777","article-title":"Brain-gut axis dysfunction in the pathogenesis of traumatic brain injury","volume":"131","author":"Hanscom","year":"2021","journal-title":"J. Clin. Investigation"},{"key":"10.1016\/j.intimp.2022.108595_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117747","article-title":"Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis","volume":"253","author":"Xu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.108595_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106317","article-title":"Inhibiting NLRP3 inflammasome with MCC950 ameliorates perioperative neurocognitive disorders, suppressing neuroinflammation in the hippocampus in aged mice","volume":"82","author":"Fu","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0470","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2014.3558","article-title":"Inflammation and neuroprotection in traumatic brain injury","volume":"72","author":"Corps","year":"2015","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0475","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/neu.2017.5344","article-title":"MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury","volume":"35","author":"Ismael","year":"2018","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.intimp.2022.108595_b0480","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nbd.2018.05.016","article-title":"Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury","volume":"117","author":"Xu","year":"2018","journal-title":"Neurobiol. Disease"},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0485","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/STROKEAHA.117.018904","article-title":"Selective NLRP3 (pyrin domain\u2013containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage","volume":"49","author":"Ren","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.intimp.2022.108595_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117638","article-title":"Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion","volume":"251","author":"Wang","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-24350-x","article-title":"Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke","volume":"8","author":"Ismael","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108595_b0500","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.brainresbull.2019.01.027","article-title":"MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats","volume":"146","author":"Luo","year":"2019","journal-title":"Brain Res. Bull."},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0505","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s11064-020-03063-6","article-title":"MCC950 inhibits NLRP3 inflammasome and alleviates axonal injures in early stages of diffuse axonal injury in rats","volume":"45","author":"Zhao","year":"2020","journal-title":"Neurochem. Res."},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0510","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2022.108595_b0515","first-page":"A7558","article-title":"Mcc950 a novel inhibitor of Nlrp3 inflammasome reduces migration and invasion of lung adenocarcinoma in-vitro, D110. Cellular and molecular investigations in thoracic oncology","author":"Siterman","year":"2017","journal-title":"American Thoracic Society"},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0520","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00432-020-03274-y","article-title":"The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation","volume":"146","author":"Yaw","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108595_b0525","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2169\/internalmedicine.48.1741","article-title":"Acute lung injury review","volume":"48","author":"Tsushima","year":"2009","journal-title":"Intern. Med."},{"key":"10.1016\/j.intimp.2022.108595_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107506","article-title":"Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-\u03baB-mediated-MAPK and NLRP3-caspase pathways","volume":"97","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0535","first-page":"1166","article-title":"Protective effect of MCC950 against lung injury induced by mitochondrial damage-associated molecular patterns","volume":"30","author":"Peng","year":"2017","journal-title":"J. Med. Postgraduates"},{"key":"10.1016\/j.intimp.2022.108595_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115954","article-title":"MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice","volume":"30","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0545","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.bbrc.2018.08.089","article-title":"The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury","volume":"503","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2022.108595_b0550","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2022.108595_b0555","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.intimp.2019.02.016","article-title":"The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice","volume":"70","author":"Qu","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-26775-w","article-title":"MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice","volume":"8","author":"Perera","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0565","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10787-020-00730-6","article-title":"Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90\/NLRP3 interaction and inducing autophagy in rats","volume":"29","author":"Saber","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"4","key":"10.1016\/j.intimp.2022.108595_b0570","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cvr\/cvy252","article-title":"Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension","volume":"115","author":"Krishnan","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"10","key":"10.1016\/j.intimp.2022.108595_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03076-7","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1 \u03b2\/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model","volume":"11","author":"Sui","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2022.108595_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106394","article-title":"Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model","volume":"83","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108595_b0585","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/TP.0000000000003208","article-title":"Nlrp3 inflammasome inhibitor MCC950 ameliorates Obliterative bronchiolitis by inhibiting Th1\/Th17 response and promoting treg response after orthotopic tracheal transplantation in mice","volume":"104","author":"Xu","year":"2020","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.intimp.2022.108595_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-020-00251-7","article-title":"NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-\u03baB\/COX-2\/PG pathway","volume":"17","author":"Tang","year":"2020","journal-title":"J. Inflamm."},{"issue":"11","key":"10.1016\/j.intimp.2022.108595_b0595","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.3390\/ijms19113289","article-title":"The small molecule NLRP3 inflammasome inhibitor MCC950 does not alter wound healing in obese mice","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108595_b0600","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","article-title":"Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950","volume":"73","author":"Corcoran","year":"2021","journal-title":"Pharmacol. Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:37:59Z","timestamp":1761586679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":120,"alternative-id":["S1567576922000790"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108595","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108595"}}